Medtronic snaps up smart insulin pen maker Companion Medical in a ‘bold move’
Medtronic is buying up leading smart insulin pen and connected phone app maker Companion Medical as it looks to shore up its growing weakness in the pump market.
Medtronic is buying up leading smart insulin pen and connected phone app maker Companion Medical as it looks to shore up its growing weakness in the pump market.
As the coronavirus pandemic paralyzed most nonemergency medical practices this spring, the dialysis business, vital to the survival of patients with kidney disease, rolled ahead and in some cases grew.
Fractyl Laboratories, developers of a minimally invasive procedure to resurface the inner linings of the intestine, has raised $55 million to help complete its pivotal clinical trial in type 2 diabetes.
Roche’s batch of phase 3 tests of its experimental GI drug etrolizumab has not gone to plan, with “mixed results” highlighting a murky picture for its ulcerative colitis (UC) program.
Guardant Health received a milestone approval from the FDA for its cancer test, as the first liquid biopsy able to genetically profile solid tumors anywhere in the body through a single blood draw.
The arrhythmia-focused Acutus Medical has moved forward with its IPO, with plans to raise about $158.8 million to help expand its commercial teams and complete the clinical testing of its heart-mapping catheters.
Creating new, successful central nervous system drugs is tough, and Lundbeck knows this better than most after canning an internal CNS effort.
Dicerna Pharmaceuticals has shared interim phase 1 data on its Roche-partnered hepatitis B drug RG6346. The trial linked RG6346 to reductions in hepatitis B surface antigen (HBsAg) that suggest the RNAi therapy can hold its own against rival candidates in development at Johnson & Johnson and Vir Biotechnology.
AstraZeneca tapped Eko, maker of artificial intelligence-powered stethoscopes, to build new digital tools that can help screen for early signs of heart disease on a global scale.
Telehealth giant Teladoc has moved to absorb the digital disease management company Livongo through a deal worth as much as $18.5 billion, reflecting the growing importance of virtual healthcare platforms as the world is caught in the wake of the COVID-19 pandemic.